Vitality Watch

Dossier pubmed review 04-jun-2026
Narrative review or expert overview without new data

Response to “Beyond Weight Loss: A Geriatric Perspective on GLP-1 RAs in Older Adults With Obesity”.

Key claim: Geriatric clinicians debate the balance of benefits and risks, including lean mass loss and tolerability, when using GLP-1 receptor agonists to treat obesity in older adults.

Abstract

No abstract available.

Why this matters

Geriatric clinicians debate the balance of benefits and risks, including lean mass loss and tolerability, when using GLP-1 receptor agonists to treat obesity in older adults.

Source

Link

Briefing card

Response to "Beyond Weight Loss: A Geriatric Perspective on GLP-1 RAs in Older Adults With Obesity".
Stage: review · pubmed · 04-jun-2026

Geriatric clinicians debate the balance of benefits and risks, including lean mass loss and tolerability, when using GLP-1 receptor agonists to treat obesity in older adults.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1002/oby.70232

build build 880 · 2bcef25 · 2026-11-18